...
首页> 外文期刊>Journal of Thoracic Disease >Ten-year experience with endobronchial ultrasound-guided transbronchial needle aspiration: single center results in mediastinal diagnostic and staging
【24h】

Ten-year experience with endobronchial ultrasound-guided transbronchial needle aspiration: single center results in mediastinal diagnostic and staging

机译:支气管内超声引导下经支气管针抽吸的十年经验:纵隔诊断和分期的单中心结果

获取原文

摘要

Background: Endobronchial ultrasonography with transbronchial needle aspiration (EBUS-TBNA) is recognized as an accurate and minimal invasive procedure for diagnosis and staging of lung cancer and lymph nodal malignancies. EBUS is recommended as the first choice procedure for mediastinal staging in lung cancer in international guidelines. Methods: A retrospective evaluation was performed on single center experience with EBUS-TBNA in our thoracic surgery department in a 10-year time frame. Main indication for the procedure was suspected non-lymphomatous malignancy in intrathoracic lymph-nodes on computed tomography (CT) or positron emission tomography (PET) scan. All procedures were performed under conscious sedation in a day-hospital setting. All the aspirated specimens were obtained with a 22-gauge needle and were fixed in 10% formalin and paraffin embedded. Sections of 3 micron in thickness were cut and hematoxylin-eosin stained. Results: From October 2005 to August 2016, 496 patients were submitted to EBUS-TBNA. Number of nodal stations punctured was 592 with a mean of 2.25 punctures per patient. Diagnosis of malignancy was obtained in 291 patients (58.6%). In 25 cases a nodal metastasis from an extrathoracic primary tumor was diagnosed. Sensitivity, specificity and diagnostic accuracy were 95%, 100% and 96% respectively. Negative predictive value was 90% and positive predictive value (PPV) was 100%. When molecular tests were requested, mutational analysis was successfully performed on cell block derived material in 55 out of 56 cases (98.2%), and fluorescence in situ hybridization (FISH) analysis in 26 out of 27 cases (96.2%). Conclusions: EBUS-TBNA in our setting was an accurate and safe tool to diagnose non-lymphomatous nodal malignancies. Interestingly, in our series EBUS-TBNA has demonstrated to yield sufficient tissue for molecular analysis.
机译:背景:经支气管针吸的支气管内超声检查(EBUS-TBNA)被认为是诊断和分期肺癌和淋巴结恶性肿瘤的准确,微创方法。在国际指南中,EBUS被推荐为肺癌纵隔分期的首选方法。方法:对我们胸外科的EBUS-TBNA在10年内的单中心经验进行回顾性评估。该程序的主要指征是在计算机断层扫描(CT)或正电子发射断层扫描(PET)扫描中怀疑胸腔内淋巴结有非淋巴瘤性恶性肿瘤。所有手术均在医院白天在有意识的镇静下进行。所有吸出的标本均用22号针头获得,并固定在10%福尔马林中,石蜡包埋。切成3微米厚的切片,并对苏木精-伊红染色。结果:从2005年10月到2016年8月,有496例患者接受了EBUS-TBNA治疗。穿刺的淋巴结数目为592,每位患者平均穿刺2.25。 291例(58.6%)获得了恶性诊断。在25例病例中,诊断出了胸外原发肿瘤的淋巴结转移。敏感性,特异性和诊断准确性分别为95%,100%和96%。阴性预测值为90%,阳性预测值(PPV)为100%。当需要进行分子检测时,成功地对56例病例中的55例(98.2%)进行了细胞块衍生材料的突变分析,对27例病例中的26例(96.2%)进行了荧光原位杂交(FISH)分析。结论:在我们的环境中,EBUS-TBNA是诊断非淋巴结性淋巴结恶性肿瘤的准确和安全的工具。有趣的是,在我们的系列中,EBUS-TBNA已证明可以产生足够的组织用于分子分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号